Biosimilars Disrupt Pricing: How Policy and Market Dynamics Redefine Pharmaceutical Capital
Biosimilars are redefining pharmaceutical pricing by aligning regulatory reforms, manufacturing efficiencies, and value‑based reimbursement, reshaping both market power and career trajectories.
























